Juvenile (~2-week old) bovine stifles were from San Jose Valley Veal and Beef (Santa Clara, CA). Biopsy punches were from Integra Miltex (York, PA). Protease Inhibitor Cocktail Set I and phosphate buffered saline (PBS) tablets (140 mM NaCl, 10 mM phosphate buffer, 3 mM KCl reconstituted in 1L of deionized H2O) were from Calbiochem (San Diego, CA). Omnipaque was from GE Healthcare (Chicago, IL) and contained either 350 mg/mL (Omnipaque 350, 844 mOsm/kg, 541mOsm/L) or 300 mg/mL (Omnipaque 300, 672mOsm/kg, 465mOsm/L) of iodine in the form of iohexol, 1.21 mg/mL tromethamine, and 0.1 mg/mL edetate calcium disodium, with a reported pH between 6.8–7.730 .
Omnipaque
Manufactured by GE Healthcare
Sourced in United States, China, Norway, Ireland, United Kingdom, Germany, Italy, France, New Zealand, Spain
Omnipaque is a radiographic contrast agent developed by GE Healthcare. It is used to enhance the visibility of internal structures during medical imaging procedures, such as computed tomography (CT) scans and angiography. Omnipaque contains the active ingredient iohexol, which is an iodinated compound that temporarily increases the absorption of X-rays, allowing for better visualization of the target tissues or structures.
Automatically generated - may contain errors
Lab products found in correlation
Somatom definition flash, by Siemens (21 mentions)
Lightspeed vct, by GE Healthcare (9 mentions)
Iohexol, by GE Healthcare (8 mentions)
Brilliance ict, by Philips (8 mentions)
Somatom force, by Siemens (7 mentions)
Visipaque, by GE Healthcare (7 mentions)
Discovery ct750 hd, by GE Healthcare (6 mentions)
Aquilion one, by Toshiba (6 mentions)
Ultravist, by Bayer (6 mentions)
Isovue, by Bracco (5 mentions)
Revolution ct, by GE Healthcare (4 mentions)
Somatom definition as, by Siemens (4 mentions)
Advantage workstation 4, by GE Healthcare (4 mentions)
Somatom sensation, by Siemens (4 mentions)
Brilliance 64, by Philips (4 mentions)
Vistron ct injection system, by Bayer (3 mentions)
Xenetix, by Guerbet (3 mentions)
Discovery hd 750, by GE Healthcare (3 mentions)
Lightspeed pro 16, by GE Healthcare (3 mentions)
Locus ultra, by GE Healthcare (3 mentions)
248 protocols using omnipaque
1
Bovine Stifle Biopsy and Omnipaque Characterization
2
Percutaneous Revascularization of Distal Pulmonary Artery Atresia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The perfusable bioprinted PA model was used to simulate a proposed interventional procedure to treat distal PA atresia. The perfusable vessel was first engaged with a sheath and imaged with Omnipaque (GE Healthcare) under fluoroscopic guidance and images were obtained utilizing biplane fluoroscopy (Toshiba). The atretic vessel was cannulated under direct fluoroscopic visualization with a coronary total occlusion wire (Pilot 1.5 g, Abbott) and a microcatheter (Turnpike, Teleflex). Subsequently, a 4F glide catheter (Terumo) was passed along the coronary wire with the microcatheter for a coaxial system to create a position for soft wire probing. A runthrough 0.14″ coronary wire (Terumo) was carefully passed into the atretic vessel lumen and the connection was subsequently established with a 3×15 mm stent (Promus Premier Everolimus‐Eluting Stent, Boston Scientific Corporation). Repeat angiography was used to examine flow within vascular lumens. The procedure was performed on the benchtop (Video S1 and Figure S3 ) for phantom optimization and repeated in the cardiac catheterization laboratory to simulate the clinical setting (Figure S2 and Video S2 ). Anastomosed vessels were then manually perfused with contrast agent (Omnipaque, Novaplus) postprocedure for at least 30 seconds to verify restored flow into both vessels.
3
Rapid Stroke Imaging Workflow
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The computed tomography (CT) stroke protocol was performed on a dual source CT scanner (Siemens Definition Flash). Pre- and post-contrast CT scans of the head with the following parameters were performed: 120 kilovolts (peak) (kVp), 220 mA (auto), 64 × 0.6 mm collimation, 0.28 s/rotation, and table speed of 1 mm/rotation; CT angiography was performed from the aortic arch to the vertex with the following parameters: total 60cc of iodinated contrast agent was injected at 5 ml/s (Iohexol, Omnipaque, 350 mg iodine/ml; GE Healthcare, Piscataway, NJ), 5- to 10-second delay, 100/140 kVp, auto mA, 0.28 s/rotation, 0.6-mm-thick sections, and table speed of 4 cm/rotation. CTA data were automatically processed by the technicians, including multiplanar 5 mm maximum intensity projection reconstructions and 5-mm axial reformates or CTA source images.
The CTP technique included 45-second scanning reconstructed at 0.5-second intervals to produce a series of 90 sequential images for each of the 8 sections, covering a total of 40 mm from the basal ganglia to the lateral ventricles. CTP scanning parameters were the following: 80 kVp, 150 mA, total 50cc iodinated contrast agent injected at the rate of 5 ml/s.
The CTP technique included 45-second scanning reconstructed at 0.5-second intervals to produce a series of 90 sequential images for each of the 8 sections, covering a total of 40 mm from the basal ganglia to the lateral ventricles. CTP scanning parameters were the following: 80 kVp, 150 mA, total 50cc iodinated contrast agent injected at the rate of 5 ml/s.
4
Robotic Angiographic Foot Perfusion Imaging
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
DSAs were performed using a robotic flat panel, multi-axis, interventional angiographic system (Artis zeego, Siemens Healthcare, Forchheim, Germany) in a hybrid operating theatre. A 10 mL bolus of 50% diluted iohexol contrast medium (Omnipaque, GE Healthcare, Amersham, UK) was hand injected via an antegrade transfemoral 10 cm 5 F sheath for the DSA sequence. In all patients, access was obtained via the common femoral artery. No saline flushes were used during the DSA acquisition phase. Pre- and post-endovascular intervention DSA images of the foot were acquired at four frames per second until all foot pedal vessels were fully opacified and subsequently washed out.
5
Iohexol-Induced Vero Cell Injury
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Vero cells were treated with different concentrations of iohexol (OMNIPAQUE™, 350 mg iodine per mL, GE Healthcare, India) in a graded manner (12.5 mg/mL to 200 mg of iodine/mL) to determine the optimal dose at which significant cellular injury occurred as reflected by the characteristic morphological changes on microscopy in comparison with a control group. Cells exposed to iohexol show signs of rounding up. In contrast, the control healthy cells retain their primary elongated shape. The cell viability was further assessed by MTT assay as described below (Figure 1 ) by exposing the Vero cells to increasing doses of iohexol. An effective dose of 100 mg iodine per mL of iohexol was used for the successive experiments.
6
Newtonian Placebo Formulation and Characterization
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Newtonian placebos were commercial iohexol contrast solutions with nominal viscosities of 2.3 cP, 10 cP, and 20 cP at 20 °C (Omnipaque™ 140 mg, 300 mg, and 350 mg iodine/mL, respectively; GE Healthcare, Oslo, Norway). Additional higher viscosity placebo solutions were custom formulated at 30 cP, 40 cP, and 50 cP from iohexol contrast (reagent grade, Sigma-Aldrich HistodenzTM, St. Louis, MO) with dextran (Dextran 40 MW 40,000, pharmaceutical grade, Pharmacosmos, Holbaek, Denmark) added as a viscosity modifier. Placebo viscosities were confirmed on a Brookfield LVDV III + rheometer (AMATEK Brookfield, Middleborough, MA) at 20 °C using a CPE-40 spindle. Shear rate scans were performed manually for each solution between 10% and 100% full scale range. Injection placebo densities were measured on a DMA 4500M densitometer (Anton Paar, Graz, Austria) at 20.00 °C, 21.50 °C, and 23.00 °C. Pre-fillable syringes were manually filled with 2.0 mL of the target solution using a positive displacement pipette followed by vacuum stoppering.
7
Preparation of Re- and I-XCA Solutions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Re- and I-XCA with a final concentration of rhenium and iodine of 50, 100, and 200 mM were prepared by diluting ammonium perrhenate (Sigma-Aldrich; Oakville, Ontario, Canada) and iohexol (Omnipaque™, 300 mg of I per mL, GE Healthcare; Little Chalfont, Buckinghamshire, United Kingdom), which is a clinically used I-XCA, in water.
8
Whole-Brain CT Perfusion for Endovascular Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients underwent whole-brain CTP within 3 days before and 3 days after the
endovascular treatment. CTP images were acquired using a 256-slice axial CT
scanner (GE Revolution CT). Contrast agent, 50 ml (Omnipaque, 350 mg I/ml; GE
Healthcare, Shanghai, CN) was injected into the antecubital vein at a rate of
5 ml/s using an automated injector (Ulrich Injection System; Ulrich GMBH &
Co. KG, Germany). After a 5-s delay, CTP was performed with the following
acquisition parameters: 80 kV tube voltage, 150 mA, 5 mm slice thickness,
256 × 0.625 mm collimation, 0.5 s rotation time, 2.0 s cycle time, 25-cm field
of view (FOV), 512 × 512 image matrix size, and 32 slices. A total of 512 slices
were obtained with a 160 mm scan length and scan time of about 40 s.
endovascular treatment. CTP images were acquired using a 256-slice axial CT
scanner (GE Revolution CT). Contrast agent, 50 ml (Omnipaque, 350 mg I/ml; GE
Healthcare, Shanghai, CN) was injected into the antecubital vein at a rate of
5 ml/s using an automated injector (Ulrich Injection System; Ulrich GMBH &
Co. KG, Germany). After a 5-s delay, CTP was performed with the following
acquisition parameters: 80 kV tube voltage, 150 mA, 5 mm slice thickness,
256 × 0.625 mm collimation, 0.5 s rotation time, 2.0 s cycle time, 25-cm field
of view (FOV), 512 × 512 image matrix size, and 32 slices. A total of 512 slices
were obtained with a 160 mm scan length and scan time of about 40 s.
9
Characterization of Iohexol Nanoparticles
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All the chemicals were obtained from Sigma Aldrich (St Louis, MO, USA) and used without further purification, unless otherwise specified. Iohexol (Omnipaque™) was obtained from GE Healthcare (UK). MitoTracker® Red CMXRos, Image-iT®-DEAD Green™ viability, HCS Cell Mask™ deep red and Hoechst 33342 (trihydrochloride, trihydrate) were purchased from Life Technologies (Oregon, USA). Sucrose was acquired from VWR International Ltd (England, UK) and paraformaldehyde solution 37–41% was acquired from Fisher Scientific (England, UK). A spectrum 100 spectrometer (PerkinElmer) was used to perform IR measurements. Dynamic light scattering (DLS) and Z-potential were measured using a Zetasizer Nanoseries spectrophotometer (Malvern instruments) at 25 °C. TEM samples were prepared on carbon-coated copper grids (200 mesh, Agar scientific) and TEM images were acquired using a Tecnai T20 instrument (FEI). Powder-XRD data were obtained on a Bruker D8 Advance powder diffractometer with a Cu Kα X-ray source (λ = 1.54058 Å) operating at 40 kV and 40 mA and a Sol-X detector.
10
Individualized Contrast-Enhanced CT Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Participants were examined first by LDCT followed directly by SDCT. All CT examinations were performed using a 64‐slice General Electric (GE) Optima CT660 machine (GE Healthcare, Marlborough, Massachusetts, USA). The CT examination protocols are shown in Table
1 . All patients received iodine‐based intravenous contrast material Omnipaque™ (GE Healthcare) at a concentration of 350 mg iodine per ml over a constant injection time of 30 s. The contrast dosage was individualized based on the patient's age, height and weight using OmniVis™ software version 5.0 (GE Healthcare) for calculations; thus, the injection rate varied with the total contrast dosage. Time delay was individualized using SmartPrep (GE Healthcare) with a region of interest in the abdominal aorta (threshold 100 Hounsfield units) and calculated time delay for the portal venous phase. From the raw data for both CT acquisitions, 5‐mm slices in three planes were reformatted using iterative reconstructions, adaptive statistical iterative reconstructions and/or dose reduction. Patients received intravenous contrast only; no oral or rectal contrast was used. All contrast CT studies were done with the portal venous phase
only.
only.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!